Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Artemisia tridentata pollen is a non-standardized allergenic extract derived from the pollen of the Artemisia tridentata plant, commonly known as Big Sagebrush. [1] It is a biologic product used for the diagnosis and treatment of type I hypersensitivity reactions (allergies) to sagebrush pollen, a significant cause of hay fever (allergic rhinitis) and allergic asthma, particularly in the western United States. [1, 2, 4] For diagnostic purposes, the extract is used in skin prick tests to identify sensitization by eliciting a localized allergic reaction. [13] For therapeutic use, it is administered as allergen-specific immunotherapy (e.g., allergy shots or sublingual drops), which aims to induce immune tolerance. [5, 6] This process is thought to involve modulating the immune system's response to the pollen, shifting it from an allergic Th2 response to a more tolerant Th1/Treg response. [16, 17] The extract exhibits significant cross-reactivity with pollens from other Artemisia species (like mugwort), making it potentially useful for diagnosing and treating a broader range of sagebrush and mugwort allergies. [9]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on artemisia tridentata pollen.